Exosomes and cancer-Diagnostic and prognostic biomarkers and therapeutic vehicle

X Wang, L Tian, J Lu, IOL Ng - Oncogenesis, 2022 - nature.com
Exosomes belong to a subpopulation of extracellular vesicles secreted by the dynamic
multistep endocytosis process and carry diverse functional molecular cargoes, including …

[HTML][HTML] Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings

F de Galiza Barbosa, MA Queiroz, RF Nunes, LB Costa… - Cancer Imaging, 2020 - Springer
PSMA PET imaging was originally used to assess biochemical recurrence of prostate cancer
(PCa), but its clinical use was promptly extended to detection, staging and therapy response …

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

V Narayan, JS Barber-Rotenberg, IY Jung, SF Lacey… - Nature medicine, 2022 - nature.com
Chimeric antigen receptor (CAR) T cells have demonstrated promising efficacy, particularly
in hematologic malignancies. One challenge regarding CAR T cells in solid tumors is the …

Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer

Z Szabo, E Mena, SP Rowe, D Plyku, R Nidal… - Molecular imaging and …, 2015 - Springer
Purpose Prostate-specific membrane antigen (PSMA) is a recognized target for imaging
prostate cancer. Here we present initial safety, biodistribution, and radiation dosimetry …

Theranostics in nuclear medicine practice

A Yordanova, E Eppard, S Kürpig… - OncoTargets and …, 2017 - Taylor & Francis
The importance of personalized medicine has been growing, mainly due to a more urgent
need to avoid unnecessary and expensive treatments. In nuclear medicine, the theranostic …

Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy

CM Zechmann, A Afshar-Oromieh, T Armor… - European journal of …, 2014 - Springer
Introduction Since the prostate-specific membrane antigen (PSMA) is frequently over-
expressed in prostate cancer (PCa) several PSMA-targeting molecules are under …

The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: A review insights from phase 2 and 3 studies

P Yu, C Zhu, X You, W Gu, X Wang, Y Wang, R Bu… - Cell Death & …, 2024 - nature.com
With the high incidence of urogenital tumors worldwide, urinary system tumors are among
the top 10 most common tumors in men, with prostate cancer ranking first and bladder …

PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis

S Bravaccini, M Puccetti, M Bocchini, S Ravaioli… - Scientific reports, 2018 - nature.com
Prostate cancer (PCa) patients are risk-stratified on the basis of clinical stage and PSA level
at diagnosis and the Gleason Score (GS) in prostate biopsy. However, these parameters are …

PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy

W Jones, K Griffiths, PC Barata, CJ Paller - Cancers, 2020 - mdpi.com
Prostate-specific membrane antigen (PSMA) has been the subject of extensive investigation
in the past two decades as a promising molecular target for prostate cancer (PCa). Its …

Prostate-specific membrane antigen targeted gold nanoparticles for theranostics of prostate cancer

JD Mangadlao, X Wang, C McCleese, M Escamilla… - ACS …, 2018 - ACS Publications
Prostate cancer is one of the most common cancers and among the leading causes of
cancer deaths in the United States. Men diagnosed with the disease typically undergo …